Advancements in the Multiple Myeloma Treatment Paradigm

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS;Jordyn Sava

June 14th 2024

AFM13/NK Cell Combination Shows Encouraging Responses in R/R Lymphoma

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Tony Berberabe, MPH

Advancing Myeloma Treatment With Blood-Based MRD Testing

AFM13-NK combo shows high response rates in relapsed/refractory lymphoma trial, per survival data reported at 20 months.

Jordyn Sava;Ben Derman, MD

February 15th 2024

FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Related Content

Interviews

MULTIPLE MYELOMA

HEMATOLOGY

Targeted Oncology Staff

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS;Jordyn Sava

June 14th 2024

AFM13/NK Cell Combination Shows Encouraging Responses in R/R Lymphoma

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Tony Berberabe, MPH

Advancing Myeloma Treatment With Blood-Based MRD Testing

AFM13-NK combo shows high response rates in relapsed/refractory lymphoma trial, per survival data reported at 20 months.

Jordyn Sava;Ben Derman, MD

February 15th 2024

FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.